Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The neuronal strategy for inflammation.

Luis Ulloa1, Ping Wang

  • 1Feinstein Institute of Biomedical Research, Department of Surgery, North Shore University Hospital, 350 Community Drive, Manhasset, NY 11030, USA.

Novartis Foundation Symposium
|March 27, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decoding acupuncture somatotopic maps for neuromodulation.

Neuron·2025
Same author

Data analysis protocol for early autonomic dysfunction characterization after severe traumatic brain injury.

Frontiers in neurology·2025
Same author

Vagal stimulation ameliorates murine colitis by regulating SUMOylation.

Science translational medicine·2024
Same author

Vagal sensory neuron-derived FGF3 controls insulin secretion.

Developmental cell·2024
Same author

Personal versus therapist perioperative music intervention: a randomized controlled trial.

International journal of surgery (London, England)·2024
Same author

Complementary and alternative medicine on cognitive defects and neuroinflammation after sepsis.

Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan·2024
Same journal

Genetic and therapeutic control of diabetogenic CD8+ T cells.

Novartis Foundation symposium·2009
Same journal

Translating mucosal antigen based prevention of autoimmune diabetes to human.

Novartis Foundation symposium·2009
Same journal

Re-establishing immune tolerance in type 1 diabetes via regulatory T cells.

Novartis Foundation symposium·2009
Same journal

Immune markers of disease and therapeutic intervention in type 1 diabetes.

Novartis Foundation symposium·2009
Same journal

Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of beta cell mass.

Novartis Foundation symposium·2009
Same journal

CD8 and cytotoxic T cells in type 1 diabetes.

Novartis Foundation symposium·2009
See all related articles

The nervous system regulates inflammation via the nicotinic anti-inflammatory pathway. Nicotinic agonists show promise in treating sepsis by reducing inflammation and improving survival.

Area of Science:

  • Immunology
  • Neuroscience
  • Pharmacology

Background:

  • Severe sepsis is a life-threatening condition driven by inflammation.
  • The nervous system plays a role in regulating immune responses and inflammation.
  • Acetylcholine acts as an anti-inflammatory cytokine via the nicotinic anti-inflammatory pathway.

Purpose of the Study:

  • To investigate the role of the alpha7-nicotinic acetylcholine receptor (alpha7n AChR) in modulating inflammation during sepsis.
  • To evaluate the therapeutic potential of nicotinic agonists in experimental sepsis models.

Main Methods:

  • Utilized experimental sepsis models.
  • Administered nicotinic agonists to assess their effects on inflammation and survival.
  • Investigated the mechanism involving the NF-kappaB pathway and pro-inflammatory cytokine production in macrophages.

Related Experiment Videos

Main Results:

  • Nicotine demonstrated greater efficacy than acetylcholine in inhibiting the NF-kappaB pathway.
  • Nicotinic agonists significantly attenuated systemic inflammation and improved survival rates in experimental sepsis.
  • The anti-inflammatory effects were dependent on the alpha7-nicotinic acetylcholine receptor (alpha7n AChR).

Conclusions:

  • The alpha7n AChR is a key mediator in the nicotinic anti-inflammatory pathway.
  • Selective nicotinic agonists targeting alpha7n AChR represent a potential therapeutic strategy for sepsis and other inflammatory diseases.
  • Further development of selective agonists could overcome nicotine's toxicity limitations.